Leti Fatjon, Malenica Ivana, Doshi Meera, Courtright Amanda, Van Keuren-Jensen Kendall, Legendre Christophe, Still Christopher D, Gerhard Glenn S, DiStefano Johanna K
Division of Diabetes, Cardiovascular and Metabolic Diseases, Translational Genomics Research Institute, Phoenix, Ariz.
Department of Gastroenterology and Nutrition, Geisinger Obesity Institute, Danville, PA.
Transl Res. 2015 Sep;166(3):304-14. doi: 10.1016/j.trsl.2015.04.014. Epub 2015 May 4.
Recent evidence suggests that microRNAs (miRNAs), small, noncoding RNA molecules that regulate gene expression, may play a role in the regulation of metabolic disorders, including nonalcoholic fatty liver disease (NAFLD). To identify miRNAs that mediate NAFLD-related fibrosis, we used high-throughput sequencing to assess miRNAs obtained from liver biopsies of 15 individuals without NAFLD fibrosis (F0) and 15 individuals with severe NAFLD fibrosis or cirrhosis (F3-F4), matched for age, sex, body mass index, type 2 diabetes status, hemoglobin A1c, and use of diabetes medications. We used DESeq2 and Kruskal-Wallis test to identify miRNAs that were differentially expressed between NAFLD patients with or without fibrosis, adjusting for multiple testing using Bonferroni correction. We identified a total of 75 miRNAs showing statistically significant evidence (adjusted P value <0.05) for differential expression between the 2 groups, including 30 upregulated and 45 downregulated miRNAs. Quantitative reverse-transcription polymerase chain reaction analysis of selected miRNAs identified by sequencing validated 9 of 11 of the top differentially expressed miRNAs. We performed functional enrichment analysis of dysregulated miRNAs and identified several potential gene targets related to NAFLD-related fibrosis including hepatic fibrosis, hepatic stellate cell activation, transforming growth factor beta signaling, and apoptosis signaling. We identified forkhead box O3 and F-box WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7) as potential targets of miR-182, and found that levels of forkhead box O3, but not FBXW7, were significantly decreased in fibrotic samples. These findings support a role for hepatic miRNAs in the pathogenesis of NAFLD-related fibrosis and yield possible new insight into the molecular mechanisms underlying the initiation and progression of liver fibrosis and cirrhosis.
近期证据表明,微小RNA(miRNA),即调节基因表达的小型非编码RNA分子,可能在包括非酒精性脂肪性肝病(NAFLD)在内的代谢紊乱调节中发挥作用。为了鉴定介导NAFLD相关纤维化的miRNA,我们使用高通量测序来评估从15名无NAFLD纤维化(F0)个体和15名患有严重NAFLD纤维化或肝硬化(F3 - F4)个体的肝活检中获得的miRNA,这些个体在年龄、性别、体重指数、2型糖尿病状态、糖化血红蛋白以及糖尿病药物使用方面相匹配。我们使用DESeq2和Kruskal - Wallis检验来鉴定在有或无纤维化的NAFLD患者之间差异表达的miRNA,并使用Bonferroni校正对多重检验进行调整。我们总共鉴定出75个miRNA在两组之间差异表达具有统计学显著证据(校正P值<0.05),包括30个上调的和45个下调的miRNA。对通过测序鉴定的选定miRNA进行定量逆转录聚合酶链反应分析,验证了11个差异表达最显著的miRNA中的9个。我们对失调的miRNA进行了功能富集分析,并鉴定出几个与NAFLD相关纤维化相关的潜在基因靶点,包括肝纤维化、肝星状细胞活化、转化生长因子β信号传导和凋亡信号传导。我们鉴定出叉头框O3和含F - 盒WD重复结构域7的E3泛素蛋白连接酶(FBXW7)作为miR - 182的潜在靶点,并发现纤维化样本中叉头框O3的水平显著降低,但FBXW7的水平未降低。这些发现支持肝脏miRNA在NAFLD相关纤维化发病机制中的作用,并为肝纤维化和肝硬化发生及进展的分子机制提供了可能的新见解。